DLP-114-Top.jpg

DLP-114 – Risperidone 3 month Formulation

Delpor’s DLP-114 is a 3 month formulation of Risperidone. The product is using Delpor’s ProzorTM technology and the medication is released from Delpor’s subcutaneous implant device. The product is designed to deliver approximately 1.8 mg of Risperidone each day for a total period of 3 months. The system enables zero order release kinetics and it is expected to maintain approximately 20 ng/ml of Risperidone and its active metabolite in human plasma. Delpor has already completed in vitro and in vivo studies illustrating the technical feasibility of the technology and showing a strong in-vitro/in-vivo correlation.

Comments are closed.